The Swedish ACCES model: predicting the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis

The Arthritis Cost Consequence Evaluation System (ACCES) pharmacoeconomic m odel was used to evaluate the economic and health impact of the recent intr oduction of celecoxib for treatment of osteoarthritis (OA) and rheumatoid a rthritis (RA) in Sweden. The model demonstrates that use of celecoxib can b e expected to reduce the incidence of gastrointestinal adverse events, reso urce utilization and treatment costs. In a cost-effectiveness analysis, cel ecoxib demonstrated economic dominance (i.e. improved health at reduced cos t) compared with the currently available alternatives for OA, and demonstra ted economic dominance against a clinically relevant base-case scenario for RA. In sensitivity analyses, the results were shown to be relatively robus t; celecoxib demonstrated economic dominance or favourable cost-effectivene ss ratios in all analyses. Based on these data, it can be concluded that th e use of celecoxib in Sweden will provide societal benefits by improving he alth care at reduced cost for patients with OA and RA.